Clinical factors statistically associated with improved survival in 2020 were absence of smoking (HR = 0.55, [0.32–0.94], p = 0.03), age < 70 years (HR = 0.72 [0.58–0.89], p = 0.003), squamous-cell carcinomas (HR = 0.67 [0.48–0.95], p = 0.03), ECOG PS 0–1 (HR = 0.75 [0.59–0.94], p = 0.01) and 2 (HR = 0.67 [0.48–0.95], p = 0.02), Stage IV (HR= 0.75, [0.62–0.9], p = 0.003), presence of an EGFR mutation (HR = 0.37 [0.17–0.81], p = 0.01) and systemic treatment administration (HR = 0.8 [0.65–0.98], p = 0.03). Here, EGFR is linked to squamous cell carcinoma.